Could a special MRI help doctors better treat pancreatic cancer?
NCT ID NCT07705919
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This trial investigates whether a special type of MRI scan, called DCE-MRI, can better assess how well chemotherapy is working in people with borderline resectable pancreatic cancer. Participants will receive standard chemotherapy and undergo DCE-MRI scans along with regular imaging. The goal is to see if DCE-MRI provides more accurate information about tumor response, potentially helping doctors decide when surgery is most likely to be successful.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DCE-MRI imaging as a diagnostic tool
- What this could lead to
- If successful, this could lead to more accurate assessment of how well chemotherapy is working in pancreatic cancer patients, helping doctors decide the best time for surgery.
- What could go wrong
- This is an early-phase study with a small number of participants, so results may not apply to all patients. The imaging technique may not reliably predict surgical outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple attack on pancreatic cancer: radiotherapy, chemo, and immunotherapy aim to make tumors removable
- New drug targets pancreatic cancer before surgery
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- Genetic test may guide chemo choice for pancreatic cancer patients
- New chemo cocktail shows promise for pancreatic cancer patients before surgery
- Pancreatic cancer drugs put to the test in early trial